CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Efficacy and safety of Canagliflozin (CANA), an inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2), added on to insulin therapy with or without oral agents in type 2 diabetes (T2D)
DOI 10.1055/s-0033-1341911
Bibliografische Angaben
Nachweis in CareLit
Autor:innenD Matthews, G Fulcher, V Perkovic, D de Zeeuw, KW Mahaffey, J Rosenstock, M Davies, G Capuano, M Desai, W Shaw, F Vercruysse, G Meininger, B Neal
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Question: SGLT2 inhibition is a novel treatment modality for T2D. We report here a pre-specified substudy of the CANagliflozin cardioVascular Assessment Study (CANVAS) defining the efficacy and safety of CANA in subjects with T2D on insulin. Methodology: CANVAS is a double-blind, placebo (PBO)-controlled study that randomized 4,330 individuals at elevated cardiovascular risk to the addition of CANA 100 or 300 mg or…
Zitieren
Zitierempfehlung
D Matthews, G Fulcher, V Perkovic, D de Zeeuw, KW Mahaffey, J Rosenstock, M Davies, G Capuano, M Desai, W Shaw, F Vercruysse, G Meininger, B Neal (2013) Efficacy and safety of Canagliflozin (CANA), an inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2), added on to insulin therapy with or without oral agents in type 2 diabetes (T2D). Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0033-1341911
Mit CareLit weiterarbeiten